What is Osmind, Inc.?
Founded in 2020 and headquartered in San Francisco, Osmind, Inc. operates as a specialized mental health care organization. The company is primarily focused on facilitating innovative treatments, with a specific emphasis on legal psychedelic medicine, including FDA-approved ketamine and esketamine therapies. Furthermore, the platform serves as a critical digital infrastructure for clinicians involved in clinical trials for emerging treatments such as MDMA and psilocybin.
By providing a comprehensive software ecosystem, Osmind enables healthcare providers to track patient outcomes, manage complex treatment protocols, and contribute to the broader body of psychiatric research. This dual focus on patient care and data-driven clinical insights establishes Osmind as a vital link in the modernization of mental health services, bridging the gap between traditional psychiatric practices and the next generation of therapeutic interventions.
How much funding has Osmind, Inc. raised?
Osmind, Inc. has raised a total of $57M across 3 funding rounds:
Angel/Seed
$2M
Series A
$15M
Series B
$40M
Angel/Seed (2020): $2M with participation from Jeffrey Leiden MD, What If Ventures, General Catalyst Partners, and 20|20 Fund
Series A (2021): $15M led by AME Cloud Ventures, Tiger Global, Offline Ventures, General Catalyst, and Future Ventures
Series B (2022): $40M supported by DFJ Growth
Key Investors in Osmind, Inc.
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, including healthcare and enterprise software, by providing both capital and operational expertise.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides capital to companies in seed, early, and growth-stages, specifically targeting technology companies poised for market leadership.
AME Cloud Ventures
AME Cloud Ventures is a venture fund focusing on seed to later stage companies that build infrastructure and value chains around data, supporting entrepreneurs who create unique data across the technology stack.
What's next for Osmind, Inc.?
With the infusion of $40M, Osmind is poised to enter a new phase of enterprise-level growth. The strategic roadmap likely involves expanding its clinical network, deepening its data analytics capabilities, and preparing for the potential integration of new, FDA-approved psychedelic therapies into mainstream clinical practice. As the regulatory environment for these treatments continues to evolve, Osmind's role as a data-centric platform will be instrumental in standardizing care delivery and demonstrating efficacy at scale.
The company's focus will likely shift toward strengthening its market leadership by fostering deeper partnerships with research institutions and healthcare providers. By leveraging its robust capital position, Osmind is set to solidify its infrastructure, ensuring that it remains the preferred digital partner for clinics navigating the complexities of advanced mental health treatments.
